Abstract: A tether assembly may be attached to a bone to correct a rotational deformity. The bone may have a growth plate that separates a first section of the bone from a second section of the bone. The tether assembly may have a tether member with a first end, a second end, and a central portion extending between the first end and the second end. The first end may have a closed outer wall that defines and fully bounds a first aperture. The second end may have an open outer wall that defines and partially bounds a second aperture. The open outer wall may define a slot in communication with the second aperture. The first and second ends may be securable to the first and second sections of the bone via coupling members inserted through the first and second apertures and anchored in the first and second sections, respectively.

Abstract: A weather-detecting device (100) can include a substrate (102) and a detection region (106) exposed to an environment within which the weather-detecting device (100) is situated when in use. An array (110) of heating elements (112) can be mounted at a first side of the substrate (102), with at least one surface of each heating element (112) in the array (110) being positioned within the detection region (106). A controller can be electrically coupled to the array (110) of heating elements (112), and the controller can individually address each heating element (112) in the array (110) to selectively pass electrical current through each heating element (112).

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3?, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

Abstract: A technology is described for determining an intended movement from neuromuscular signals. An example method (800) includes receiving electromyography (EMG) data corresponding to single-ended channels of an electrode array (810), where EMG signals are detected by electrodes comprising the single-ended channels of the electrode array and the EMG signals are converted to the EMG data. Determining differential channel pairs for the single-ended channels of the electrode array (820) and extracting feature data from the EMG data of the differential channel pairs (830). Thereafter a feature data set is selected from the feature data of the differential channel pairs (840) and the feature data set is input to a decode model configured to correlate the feature data set to an intended movement (850). Decode output is received from the decode model indicating the intended movement (860) and the decode output is provided to a device (870).

Abstract: A bone implant system may include a plurality of bone anchors, a superior rod attachable to a superior portion of a bone via the bone anchors, and an inferior rod attachable to an inferior portion of the bone via the bone anchors. The superior rod may have a superior end, and the inferior rod may have an inferior end. The superior rod may telescopically engage the inferior rod such that a cavity is present within at least one of the superior rod and the inferior rod and such that a length of the combined superior and inferior rods, measured between the superior end and the inferior end, is adjustable. The cavity may contain a micropump and a chamber. The micropump may be configured to expel fluid into the chamber to urge the length to increase.

Abstract: A bioorthogonal molecule can include a molecule having a structure according the above wherein R1-R8 are independently selected from H, a substituted or unsubstituted C1-C4 alkyl or alkylene group, COOH, COOR9, COR9, CONR9R10, CN, CF3, and SO2R9, and where R9 and R10 are independently selected from H and a substituted or unsubstituted C1-C4 alkyl or alkylene group, with the proviso that one of R3-R8 comprises a leaving group, and wherein X is O, S, N, SO, SO2, SR+, Se, PO2?, or NRR?+, and where R and R? are independently selected from H or a substituted or unsubstituted C1-C4 alkyl or alkylene group.

Abstract: Provided are nucleotide sequences encoding polypeptides with ribonuclease III activity, wherein the nucleotide sequences have been modified to reduce their regulation by miRNAs. In some embodiments, the nucleotide sequences are at least 50% and as much as 100% identical to SEQ ID NO: 20 or SEQ ID NO: 22, and/or encode polypeptides that are at least 90% percent identical to SEQ ID NO: 23. Also provided are vectors and host cells that include the nucleotide sequences, methods for expressing the nucleotide sequences in cells, tissues, and organs, which in some embodiments can be in the eye of a subject in need thereof, methods for preventing and/or treating development of diseases or disorders and/or for restoring undesirably low DICER1 expression using the nucleotide sequences, and pharmaceutical compositions that have the presently disclosed nucleotide sequences.

Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

Abstract: A method for separating and enriching sperm from a tissue sample comprises: obtaining a microfluidic separating system having an inlet end and an outlet end, and a membrane filter (e.g., hollow fiber membrane filter) fluidly connected to the outlet end; separating the tissue sample via the microfluidic separating system into a debris fluid volume and a sperm fluid volume; and enriching the sperm fluid volume by removing excess media via the membrane filter. A two-stage tissue sample separation system comprising: a microchannel structure defining a separation fluid channel to form a separation stage; an inlet end of the microchannel structure; an outlet end of the microchannel structure; and a membrane filter fluidly connected to the outlet end for removal of at least a portion of excess media in the tissue sample.

Abstract: A bone fixation assembly may include a male member removably couplable with a female member. The male member may include a male load-sharing feature having at least one male load-sharing surface. The female member may include a female load-sharing feature having at least one female load-sharing surface. The female load-sharing feature may be positioned and shaped to receive the male load-sharing feature therein. In response to a bending load acting on the bone fixation assembly, at least one of the male member and the female member may bend such that, at least a portion of the at least one male load-sharing surface engages with at least a portion of the at least one female load-sharing surface to distribute the bending load between the male member and the female member.

Abstract: Branching phosphoramidite monomers and molecules having comb-like structures are disclosed and described. A branching phosphoramidite monomer having the structure is provided wherein R4 and R5 are independently —(O—CH2—CH2—)n where n is 1-5 or —O—(CH2—)n where n is 1-10, and R1, R2, and R3 are each one of dimethoxytrityl (DMT)—O—, levulinyl (Lev)—O—, and a phosphoramidite.

Abstract: A system for propelling a magnetic robotic device through a human comprises a magnetic actuator device operable to generate a rotating magnetic field, and a magnetic robotic device comprising a compliant body and at least two permanent magnets supported by and spatially separated about the compliant body. A non-magnetic region can also be oriented between the at least two permanent magnets. The at least two permanent magnets can be alternating or non-alternating in polarity with each other. In response to application of the rotating magnetic field generated by the magnetic actuator device and that is situated proximate the magnetic robotic device, the rotating magnetic field effectuates undulatory locomotion of the magnetic robotic device to propel the magnetic robotic device through a human, such as through a natural lumen. Further, the magnetic robotic device can optionally be supported by a catheter or endoscope to assist with propelling a distal end through a human.

Abstract: A tether assembly may be attached to a bone to correct a rotational deformity. The bone may have a growth plate that separates a first section of the bone from a second section of the bone. The tether assembly may have a tether member with a first end, a second end, and a central portion extending between the first end and the second end. The first end may have a closed outer wall that defines and fully bounds a first aperture. The second end may have an open outer wall that defines and partially bounds a second aperture. The open outer wall may define a slot in communication with the second aperture. The first and second ends may be securable to the first and second sections of the bone via coupling members inserted through the first and second apertures and anchored in the first and second sections, respectively.

Abstract: Opthalmic compositions are disclosed and described herein. In some embodiments, an ophthalmic composition can include as active agents a copper-containing agent and a secondary therapeutic agent in combination with a pharmaceutically acceptable carrier. The active agents can be present in amounts sufficient to treat myopic progression during a treatment period.

Abstract: Devices, systems, and compositions of matter involving enzyme-mediated bioelectrocatalysis are disclosed and described. An enzyme electrode can include an electrode, a bioelectric material coupled to the electrode, the bioelectric material further including a water-permeable polymer matrix, a planar linker covalently coupled to the water-permeable polymer matrix and noncovalently coupled to the electrode, and electrochemically active oxidoreductase enzyme molecules functionally embedded in the water-permeable polymer matrix.

Abstract: A device for rapid non-destructive genetic material collection can include a multi-reservoir array (202) and a movement mechanism. The multi-reservoir array (202) can include multiple reservoirs (204). A plurality of the multiple reservoirs (204) can include an abrasive surface (210) capable of retaining a source of genetic material in a liquid carrier. The abrasive surface (210) has a roughness. The movement mechanism can be operable to move the multi-reservoir array (202) in an oscillating motion sufficient to create relative movement between the abrasive surface (210) and the source of the genetic material in order to remove a portion of genetic material from the source of the genetic material without destroying the source of the genetic material or the portion of the genetic material that is removed.

Abstract: The present invention presents 2-(acylamino)imidazoles with therapeutic activity, including selective activity against cancer cells, and compositions comprising them. Methods of using and preparing the 2-(acylamino)imidazoles are also presented.

Abstract: A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.

Abstract: A phase plate for high precision wavelength extraction can include a planar substrate which has a point spread function engineered profile formed of a tessellation of regions. The point spread function engineered profile transforms a point spread function of a light source to form a wavelength dependent geometric pattern. The geometric pattern can also preserve spatial location information of the light source. Such a phase plate permits extracting three-dimensional position and the wavelength of a point emitter.

Abstract: A method for mapping shear wave velocity in biological tissues includes using an ultrasound transducer to generate mechanical excitations at a plurality of locations in a region of interest. An MRI system is used to capture a phase image of each mechanical excitation, wherein motion encoding gradients (MEGs) of the MRI system encode a propagating shear wavefront caused by the mechanical excitation. A plurality of shear wave velocity maps is generated based on the phase images, wherein each shear wave velocity map depicts velocity between adjacent propagating shear wavefronts. The shear wave speed values are combined to generate a composite shear wave velocity map of the region of interest.